logo
New Stem Cell Therapy Shows 'Promising' Results For Treating Hair Loss In Preclinical Trials

New Stem Cell Therapy Shows 'Promising' Results For Treating Hair Loss In Preclinical Trials

Gulf Insidera day ago

Researchers at the San Carlos Clinical Hospital in Madrid may have targeted a potential solution for hair loss.
A recent study analyzed the effect of injecting mice's skin with stem cells from human fat — 'adipose-derived stem cells (ASCs)' — as a means of treating androgenetic alopecia (AGA), more commonly known as male- or female-pattern hair loss.
The team found that male mice achieved the best hair regrowth after three weeks when they received low-dose ASCs, combined with an energy-boosting molecule called adenosine triphosphate (ATP).
Low-dose and high-dose ASC treatments along with ATP led to no hair regrowth improvement in females, but medium-dose ASC plus ATP led to greater regrowth.
The researchers concluded that hair regrowth was improved in 'all experimental groups' where male mice received stem cell solutions supplemented with ATP.
Researchers at the San Carlos Clinical Hospital in Madrid may have targeted a potential solution for hair loss. (iStock)
The findings were published in the journal Stem Cell Research & Therapy.
Lead study author Dr. Eduardo López Bran — dermatologist and professor at The Complutense University of Madrid — shared his expectations for the study in an interview with Fox News Digital.
'We expected good results, but not such a high level of success,' he said. 'We're talking about a very high degree of hair regrowth in both male and female mice.'
With appropriate doses, the researchers achieved 'very high percentages' of hair regrowth, noting that 100% of the male mice and up to 90% of the female mice regrew hair.
With appropriate doses, the researchers achieved 'very high percentages' of hair regrowth, noting that 100% of the male mice and up to 90% of the female mice regrew hair. (Actual mice from the study not pictured.) (iStock)
'These results demonstrate that advanced therapies may represent a new therapeutic approach for many diseases for which no effective treatments are currently available,' Bran went on.
'Achieving such promising results in the preclinical phase with a completely novel approach to androgenetic alopecia — one that avoids chronic treatment and is also safe — is a significant scientific milestone.'
'We're talking about a very high degree of hair regrowth in both male and female mice.'
The main limitation of the study was the thinness of mouse skin, Bran noted, which 'posed a challenge in administering the therapy.'
'This required the development of protocols to minimize experimental variability, and will be a key factor when studies in humans begin,' he said.
'Research advances are pointing toward possible solutions that, in the future, may offer long-lasting results without the need for continuous treatment to maintain benefits.' (iStock)
These new findings should be 'interpreted with caution and scientific rigor,' Bran cautioned.
'Although the results in mice represent significant progress, it is also true that it is essential to wait for clinical benefits in humans to be confirmed.'
The researcher encouraged those with androgenetic alopecia to continue consulting with their dermatologists and to follow prescribed treatments as research develops.
'It is important to remain hopeful. Research advances are pointing toward possible solutions that, in the future, may offer long-lasting results without the need for continuous treatment to maintain benefits,' Bran added.
'This study is small, and more research is needed on this method as a potential treatment option.'
Looking ahead to human clinical trials, researchers are 'actively working' on confirming safety for men and women between 18 and 50 years old with moderate androgenetic alopecia, the researcher noted.
'If everything progresses as expected, the most optimistic timeline points to the treatment becoming available in approximately five years,' he said.
Looking ahead to human clinical trials, researchers are 'actively working' on confirming safety for men and women between 18 and 50 years old with moderate androgenetic alopecia. (iStock)
In a separate interview with Fox News Digital, Dr. Brendan Camp, M.D., a New York-based dermatologist who was not involved in the study, commented on the potential for this method.
'While not commercially available, this study suggests that injection of stem cells supplemented with ATP into scalp skin could potentially encourage hair regrowth in individuals with androgenetic alopecia,' he reiterated.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

New Stem Cell Therapy Shows 'Promising' Results For Treating Hair Loss In Preclinical Trials
New Stem Cell Therapy Shows 'Promising' Results For Treating Hair Loss In Preclinical Trials

Gulf Insider

timea day ago

  • Gulf Insider

New Stem Cell Therapy Shows 'Promising' Results For Treating Hair Loss In Preclinical Trials

Researchers at the San Carlos Clinical Hospital in Madrid may have targeted a potential solution for hair loss. A recent study analyzed the effect of injecting mice's skin with stem cells from human fat — 'adipose-derived stem cells (ASCs)' — as a means of treating androgenetic alopecia (AGA), more commonly known as male- or female-pattern hair loss. The team found that male mice achieved the best hair regrowth after three weeks when they received low-dose ASCs, combined with an energy-boosting molecule called adenosine triphosphate (ATP). Low-dose and high-dose ASC treatments along with ATP led to no hair regrowth improvement in females, but medium-dose ASC plus ATP led to greater regrowth. The researchers concluded that hair regrowth was improved in 'all experimental groups' where male mice received stem cell solutions supplemented with ATP. Researchers at the San Carlos Clinical Hospital in Madrid may have targeted a potential solution for hair loss. (iStock) The findings were published in the journal Stem Cell Research & Therapy. Lead study author Dr. Eduardo López Bran — dermatologist and professor at The Complutense University of Madrid — shared his expectations for the study in an interview with Fox News Digital. 'We expected good results, but not such a high level of success,' he said. 'We're talking about a very high degree of hair regrowth in both male and female mice.' With appropriate doses, the researchers achieved 'very high percentages' of hair regrowth, noting that 100% of the male mice and up to 90% of the female mice regrew hair. With appropriate doses, the researchers achieved 'very high percentages' of hair regrowth, noting that 100% of the male mice and up to 90% of the female mice regrew hair. (Actual mice from the study not pictured.) (iStock) 'These results demonstrate that advanced therapies may represent a new therapeutic approach for many diseases for which no effective treatments are currently available,' Bran went on. 'Achieving such promising results in the preclinical phase with a completely novel approach to androgenetic alopecia — one that avoids chronic treatment and is also safe — is a significant scientific milestone.' 'We're talking about a very high degree of hair regrowth in both male and female mice.' The main limitation of the study was the thinness of mouse skin, Bran noted, which 'posed a challenge in administering the therapy.' 'This required the development of protocols to minimize experimental variability, and will be a key factor when studies in humans begin,' he said. 'Research advances are pointing toward possible solutions that, in the future, may offer long-lasting results without the need for continuous treatment to maintain benefits.' (iStock) These new findings should be 'interpreted with caution and scientific rigor,' Bran cautioned. 'Although the results in mice represent significant progress, it is also true that it is essential to wait for clinical benefits in humans to be confirmed.' The researcher encouraged those with androgenetic alopecia to continue consulting with their dermatologists and to follow prescribed treatments as research develops. 'It is important to remain hopeful. Research advances are pointing toward possible solutions that, in the future, may offer long-lasting results without the need for continuous treatment to maintain benefits,' Bran added. 'This study is small, and more research is needed on this method as a potential treatment option.' Looking ahead to human clinical trials, researchers are 'actively working' on confirming safety for men and women between 18 and 50 years old with moderate androgenetic alopecia, the researcher noted. 'If everything progresses as expected, the most optimistic timeline points to the treatment becoming available in approximately five years,' he said. Looking ahead to human clinical trials, researchers are 'actively working' on confirming safety for men and women between 18 and 50 years old with moderate androgenetic alopecia. (iStock) In a separate interview with Fox News Digital, Dr. Brendan Camp, M.D., a New York-based dermatologist who was not involved in the study, commented on the potential for this method. 'While not commercially available, this study suggests that injection of stem cells supplemented with ATP into scalp skin could potentially encourage hair regrowth in individuals with androgenetic alopecia,' he reiterated.

Crown Prince and Vertex Pharmaceuticals CEO Discuss Medical Milestone and Future Collaborations
Crown Prince and Vertex Pharmaceuticals CEO Discuss Medical Milestone and Future Collaborations

Bahrain News Gazette

time17-02-2025

  • Bahrain News Gazette

Crown Prince and Vertex Pharmaceuticals CEO Discuss Medical Milestone and Future Collaborations

Manama: A telephone conversation took place between His Royal Highness Prince Salman bin Hamad Al Khalifa, the Crown Prince and Prime Minister, and Dr. Reshma Kewalramani, the CEO and President of Vertex Pharmaceuticals. During the call, significant medical achievements and future collaborations were discussed. According to Bahrain News Agency, His Royal Highness highlighted Bahrain's recent medical milestone wherein the Kingdom successfully treated the world's first sickle cell disease patient outside the United States using Casgevy (exagamglogene autotemcel). This CRISPR-based gene-editing therapy was accomplished through advanced bone marrow transplantation technology. His Royal Highness reaffirmed the importance of strengthening Bahrain's partnership with Vertex Pharmaceuticals, aiming to explore future opportunities that will bolster the Kingdom's health sector. This partnership is expected to enhance Bahrain's position as a leader in scientific and medical advancements. Prince Salman emphasized Bahrain's commitment to collaborating with leading international specialized medical institutions, ensuring the Kingdom remains at the forefront of scientific progress. He stressed the importance of integrating cutting-edge treatments into the healthcare and rehabilitation services available to Bahrainis, underscoring this as a top priority for the Kingdom's health initiatives.

Nyxoah Appoints John Landry as Chief Financial Officer
Nyxoah Appoints John Landry as Chief Financial Officer

Bahrain News Gazette

time05-11-2024

  • Bahrain News Gazette

Nyxoah Appoints John Landry as Chief Financial Officer

Current CFO, Loïc Moreau, to Transition into Role of President International Mont-Saint-Guibert, Belgium – November 4, 2024, 10:45pm CET / 4:45pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ('Nyxoah' or the 'Company'), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the appointment of John Landry as Chief Financial Officer (CFO), effective November 4, 2024. This strategic appointment, in combination with the recent move to the United States of CEO Olivier Taelman, strengthens the Company's focus on the U.S. market. Mr. Landry brings over two decades of financial leadership experience in the healthcare and medtech sectors, with a proven track record of driving growth and operational efficiency in public and private companies. Most recently, he served as CFO at Vapotherm Inc., where he played an instrumental role in executing financial strategies that supported significant revenue growth and market share expansion in the U.S. market. 'We are delighted to welcome John to Nyxoah. His deep financial expertise and extensive experience in the U.S. healthcare landscape in combination with his strong investor relations experience will be invaluable as we accelerate our growth in this critical market,' said Olivier Taelman, CEO of Nyxoah. 'John's leadership will help us further optimize our financial strategies and drive operational efficiencies as we prepare Genio for commercialization in the US.' Additionally, Nyxoah announces that Loïc Moreau, currently CFO, will transition into the newly created role of President International. In this capacity, Mr. Moreau will spearhead Nyxoah's global expansion efforts, focusing on strengthening the Company's presence in key international markets. This announcement reflects Nyxoah's commitment to building a strong, diversified leadership team to support its ambitious growth objectives. About Nyxoah Nyxoah is reinventing sleep for the billion people that suffer from obstructive sleep apnea (OSA). We are a medical technology company that develops breakthrough treatment alternatives for OSA through neuromodulation. Our first innovation is Genio®, a battery-free hypoglossal neuromodulation device that is inserted through a single incision under the chin and controlled by a wearable. Through our commitment to innovation and clinical evidence, we have shown best-in-class outcomes for reducing OSA burden. Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors' therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study for FDA and U.S. commercialization approval. Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States. FORWARD-LOOKING STATEMENTS Certain statements, beliefs and opinions in this press release are forward-looking, reflecting Nyxoah's current expectations and beliefs regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah's goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; and potential receipt of FDA approval and entrance into the U.S. market. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the 'Risk Factors' section of Nyxoah's Annual Report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission ('SEC') on March 20, 2024, and subsequent reports that Nyxoah files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, Nyxoah expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither Nyxoah nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. Contacts: Nyxoah Loïc Moreau IR@ For Media In United States FINN Partners – Glenn Silver In Belgium/France Backstage Communication – Gunther De Backer gunther@ In International/Germany MC Services – Anne Hennecke nyxoah@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store